# A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT

> **NCT06491719** · NA · NOT_YET_RECRUITING · sponsor: **Beijing Friendship Hospital** · enrollment: 15 (estimated)

## Conditions studied

- CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome
- EBV
- Hemophagocytic Lymphohistiocytoses

## Interventions

- **OTHER:** NCR300（Allogenic Ipsc-derived Natural Killer cells ）

## Key facts

- **NCT ID:** NCT06491719
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2025-07-15
- **Final completion:** 2026-07-15
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06491719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06491719, "A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06491719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*